Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update

Harold J. Burstein, Sarah Temin, Holly Anderson, Thomas A. Buchholz, Nancy E. Davidson, Karen E. Gelmon, Sharon H. Giordano, Clifford A. Hudis, Diana Rowden, Alexander J. Solky, Vered Stearns, Eric P. Winer, Jennifer J. Griggs

Research output: Contribution to journalArticle

Abstract

Purpose: To update the ASCO clinical practice guideline on adjuvant endocrine therapy on the basis of emerging data on the optimal duration of treatment, particularly adjuvant tamoxifen. Methods: ASCO convened the Update Committee and conducted a systematic review of randomized clinical trials from January 2009 to June 2013 and analyzed three historical trials. Guideline recommendations were based on the Update Committee's review of the evidence. Outcomes of interest included survival, disease recurrence, and adverse events. Results: This guideline update reflects emerging data on duration of tamoxifen treatment. There have been five studies of tamoxifen treatment beyond 5 years of therapy. The two largest studies with longest reported follow-up show a breast cancer survival advantage with 10-year durations of tamoxifen use. In addition to modest gains in survival, extended therapy with tamoxifen for 10 years compared with 5 years was associated with lower risks of breast cancer recurrence and contralateral breast cancer. Recommendations: Previous ASCO guidelines recommended treatment of women who have hormone receptor-positive breast cancer and are premenopausal with 5 years of tamoxifen, and those who are postmenopausal a minimum of 5 years of adjuvant therapy with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor (in sequence). If women are pre- or perimenopausal and have received 5 years of adjuvant tamoxifen, they should be offered 10 years total duration of tamoxifen. If women are postmenopausal and have received 5 years of adjuvant tamoxifen, they should be offered the choice of continuing tamoxifen or switching to an aromatase inhibitor for 10 years total adjuvant endocrine therapy.

Original languageEnglish (US)
Pages (from-to)2255-2269
Number of pages15
JournalJournal of Clinical Oncology
Volume32
Issue number21
DOIs
StatePublished - Jul 20 2014

Fingerprint

Tamoxifen
Practice Guidelines
Hormones
Breast Neoplasms
Aromatase Inhibitors
Therapeutics
Guidelines
Survival
Recurrence
Advisory Committees
Randomized Controlled Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer : American Society of Clinical Oncology clinical practice guideline focused update. / Burstein, Harold J.; Temin, Sarah; Anderson, Holly; Buchholz, Thomas A.; Davidson, Nancy E.; Gelmon, Karen E.; Giordano, Sharon H.; Hudis, Clifford A.; Rowden, Diana; Solky, Alexander J.; Stearns, Vered; Winer, Eric P.; Griggs, Jennifer J.

In: Journal of Clinical Oncology, Vol. 32, No. 21, 20.07.2014, p. 2255-2269.

Research output: Contribution to journalArticle

Burstein, HJ, Temin, S, Anderson, H, Buchholz, TA, Davidson, NE, Gelmon, KE, Giordano, SH, Hudis, CA, Rowden, D, Solky, AJ, Stearns, V, Winer, EP & Griggs, JJ 2014, 'Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update', Journal of Clinical Oncology, vol. 32, no. 21, pp. 2255-2269. https://doi.org/10.1200/JCO.2013.54.2258
Burstein, Harold J. ; Temin, Sarah ; Anderson, Holly ; Buchholz, Thomas A. ; Davidson, Nancy E. ; Gelmon, Karen E. ; Giordano, Sharon H. ; Hudis, Clifford A. ; Rowden, Diana ; Solky, Alexander J. ; Stearns, Vered ; Winer, Eric P. ; Griggs, Jennifer J. / Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer : American Society of Clinical Oncology clinical practice guideline focused update. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 21. pp. 2255-2269.
@article{b5b14e596a93408c82241dbde84953d2,
title = "Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update",
abstract = "Purpose: To update the ASCO clinical practice guideline on adjuvant endocrine therapy on the basis of emerging data on the optimal duration of treatment, particularly adjuvant tamoxifen. Methods: ASCO convened the Update Committee and conducted a systematic review of randomized clinical trials from January 2009 to June 2013 and analyzed three historical trials. Guideline recommendations were based on the Update Committee's review of the evidence. Outcomes of interest included survival, disease recurrence, and adverse events. Results: This guideline update reflects emerging data on duration of tamoxifen treatment. There have been five studies of tamoxifen treatment beyond 5 years of therapy. The two largest studies with longest reported follow-up show a breast cancer survival advantage with 10-year durations of tamoxifen use. In addition to modest gains in survival, extended therapy with tamoxifen for 10 years compared with 5 years was associated with lower risks of breast cancer recurrence and contralateral breast cancer. Recommendations: Previous ASCO guidelines recommended treatment of women who have hormone receptor-positive breast cancer and are premenopausal with 5 years of tamoxifen, and those who are postmenopausal a minimum of 5 years of adjuvant therapy with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor (in sequence). If women are pre- or perimenopausal and have received 5 years of adjuvant tamoxifen, they should be offered 10 years total duration of tamoxifen. If women are postmenopausal and have received 5 years of adjuvant tamoxifen, they should be offered the choice of continuing tamoxifen or switching to an aromatase inhibitor for 10 years total adjuvant endocrine therapy.",
author = "Burstein, {Harold J.} and Sarah Temin and Holly Anderson and Buchholz, {Thomas A.} and Davidson, {Nancy E.} and Gelmon, {Karen E.} and Giordano, {Sharon H.} and Hudis, {Clifford A.} and Diana Rowden and Solky, {Alexander J.} and Vered Stearns and Winer, {Eric P.} and Griggs, {Jennifer J.}",
year = "2014",
month = "7",
day = "20",
doi = "10.1200/JCO.2013.54.2258",
language = "English (US)",
volume = "32",
pages = "2255--2269",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

T2 - American Society of Clinical Oncology clinical practice guideline focused update

AU - Burstein, Harold J.

AU - Temin, Sarah

AU - Anderson, Holly

AU - Buchholz, Thomas A.

AU - Davidson, Nancy E.

AU - Gelmon, Karen E.

AU - Giordano, Sharon H.

AU - Hudis, Clifford A.

AU - Rowden, Diana

AU - Solky, Alexander J.

AU - Stearns, Vered

AU - Winer, Eric P.

AU - Griggs, Jennifer J.

PY - 2014/7/20

Y1 - 2014/7/20

N2 - Purpose: To update the ASCO clinical practice guideline on adjuvant endocrine therapy on the basis of emerging data on the optimal duration of treatment, particularly adjuvant tamoxifen. Methods: ASCO convened the Update Committee and conducted a systematic review of randomized clinical trials from January 2009 to June 2013 and analyzed three historical trials. Guideline recommendations were based on the Update Committee's review of the evidence. Outcomes of interest included survival, disease recurrence, and adverse events. Results: This guideline update reflects emerging data on duration of tamoxifen treatment. There have been five studies of tamoxifen treatment beyond 5 years of therapy. The two largest studies with longest reported follow-up show a breast cancer survival advantage with 10-year durations of tamoxifen use. In addition to modest gains in survival, extended therapy with tamoxifen for 10 years compared with 5 years was associated with lower risks of breast cancer recurrence and contralateral breast cancer. Recommendations: Previous ASCO guidelines recommended treatment of women who have hormone receptor-positive breast cancer and are premenopausal with 5 years of tamoxifen, and those who are postmenopausal a minimum of 5 years of adjuvant therapy with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor (in sequence). If women are pre- or perimenopausal and have received 5 years of adjuvant tamoxifen, they should be offered 10 years total duration of tamoxifen. If women are postmenopausal and have received 5 years of adjuvant tamoxifen, they should be offered the choice of continuing tamoxifen or switching to an aromatase inhibitor for 10 years total adjuvant endocrine therapy.

AB - Purpose: To update the ASCO clinical practice guideline on adjuvant endocrine therapy on the basis of emerging data on the optimal duration of treatment, particularly adjuvant tamoxifen. Methods: ASCO convened the Update Committee and conducted a systematic review of randomized clinical trials from January 2009 to June 2013 and analyzed three historical trials. Guideline recommendations were based on the Update Committee's review of the evidence. Outcomes of interest included survival, disease recurrence, and adverse events. Results: This guideline update reflects emerging data on duration of tamoxifen treatment. There have been five studies of tamoxifen treatment beyond 5 years of therapy. The two largest studies with longest reported follow-up show a breast cancer survival advantage with 10-year durations of tamoxifen use. In addition to modest gains in survival, extended therapy with tamoxifen for 10 years compared with 5 years was associated with lower risks of breast cancer recurrence and contralateral breast cancer. Recommendations: Previous ASCO guidelines recommended treatment of women who have hormone receptor-positive breast cancer and are premenopausal with 5 years of tamoxifen, and those who are postmenopausal a minimum of 5 years of adjuvant therapy with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor (in sequence). If women are pre- or perimenopausal and have received 5 years of adjuvant tamoxifen, they should be offered 10 years total duration of tamoxifen. If women are postmenopausal and have received 5 years of adjuvant tamoxifen, they should be offered the choice of continuing tamoxifen or switching to an aromatase inhibitor for 10 years total adjuvant endocrine therapy.

UR - http://www.scopus.com/inward/record.url?scp=84905841417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905841417&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.54.2258

DO - 10.1200/JCO.2013.54.2258

M3 - Article

C2 - 24868023

AN - SCOPUS:84905841417

VL - 32

SP - 2255

EP - 2269

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -